Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). The product is indicated ...

It is available in both subcutaneous injection and intravenous infusion ... at an 85% discount to the current WAC list price of Stelara to help improve patient access to high-quality biologic ...

Emboldened by strong data for its oral IL-23 inhibitor icotrokinra in psoriasis, Johnson & Johnson has said it will see if it can outperform its big-selling injectable therapy Stelara in a head-to ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on the succession plan for its declining autoimmune blockbuster Stelara.

This approval for Crohn’s disease may make Tremfya a direct competitor with Stelara. Perspective from Edward V. Loftus Jr., MD The FDA has approved Tremfya as the “first and only ...

As we previously reported, the biosimilar was approved by the FDA in December 2024 for subcutaneous injection or intravenous ... STEQEYMA® is the sixth STELARA® biosimilar on the market in ...

If it reaches the market, JNJ-2113 could extend J&J's psoriasis franchise, currently represented by injectable IL-12 and IL-23 inhibitor Stelara (ustekinumab) – which made $2.75 billion in sales ...

The report noted that J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense deal with a private label provider, which J&J ...

STEQEYMA is available in both subcutaneous injection and intravenous infusion ... given the fact that Stelara ranks as one of the most expensive prescription drugs on the market," said Tom ...

Otulfi ® is an ustekinumab biosimilar for the reference product Stelara ® (ustekinumab ... and 90 mg/mL single-dose prefilled syringe for injection and a 130 mg/26 mL (5 mg/mL) single dose ...

Steqeyma, a biosimilar of Johnson & Johnson's blockbuster drug Stelara, received full-label approval from the US Food and Drug Administration last December for plaque psoriasis, psoriatic ...